MDM2 and neoplasm: Immunohistochemical studies using primary antibodies for MDM2 (clone SMP14, Zeta, dilution 1/230) and CDK4 (clone DCS-31, Zeta, dilution 1/230) revealed that the tumor cells in both components were immunoreactive for CDK4 (Fig. 4A).